Professional Media briefs: BMJ, Docphin, Quadrant HealthCom and BMJ.com

Occurrence of articles with honorary or ghost authorship is down, but more than one of five papers in high-impact journals has signs of inappropriate authorship, researchers wrote in BMJ. They called for more measures by journals, authors and academic institutions “to prevent a practice that might lead to loss of public confidence.”

Two MDs and an IMS Consulting Group alum started Docphin, a free web service designed to help physicians find and personalize medical news and research from journals and news sources—all from a single dashboard.

Quadrant HealthCom named Christy Tetterton and Hillary Ford group publishers. Tetterton joined the firm a year ago to manage The Journal of Family Practice and Mayo Clinic Proceedings. Ford joins the company as group publisher of the CNS division, coming from Direct Medical Data, where she was practice leader for medical publishing.

BMJ.com saw its first redesign since 2007. Among changes are navigational tabs for articles, social networking links and a free resource to help users track and record CME credits. BMJ continues to be an open access journal.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.